CompletedPhase 2NCT01349972
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- B. Smith, M.S.W., L.C.S.WSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- alvocidib(drug)
- Enrollment
- 172 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2011 – 2014
Study locations (11)
- Mayo Clinic Scottsdale-Phoenix, Scottsdale, Arizona, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- University of Chicago, Chicago, Illinois, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- Baylor University Medical Center, Dallas, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01349972 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.